James Pearle, MD
Pulmonary Disease · Orange, CANPI 1982783940
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 94.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $6,571 and has fallen 99.5% since, to $35 in 2025.
Across 28 payments — averaging $245.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- GSK$195
- Boehringer Ingelheim$148
- Neurocrine Biosciences, Inc.$19
- Bayer$17
Across 74 payments — averaging $14,773 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca AB$618K
- AstraZeneca$208K
- Teva Pharmaceuticals USA, Inc.$134K
- Cipla USA Inc.$121K
- Chiesi USA, Inc.$11K
- Novartis$2K
- plus $12 from 1 others
What the payments were for
- Consulting fees$3,35049%
- Travel & lodging$2,32134%
- Food & beverage$1,19617%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $6,489 |
| GSK | 5 | $195 |
| Boehringer Ingelheim | 2 | $148 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEVESPI AEROSPHERE$1,584
- OFEV$128
- NUCALA$120
- FASENRA$116
How this compares
$6,867 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $356,074 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $204,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $78,624 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $24,425 |
| Spiriva RespimatTiotropium Bromide | 25 | $17,579 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $15,369 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $9,236 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,243 |
| BreynaBudesonide/Formoterol Fumarate | 43 | $5,065 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $4,113 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 130 | $3,070 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $2,810 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,953 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,300 |
| Prednisone | 193 | $677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $195 | $118,418163 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $148 | $22,82237 claims |
| AstraZenecaSymbicort | $6,489 | $9,23634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Orange
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.